Testing ivarmacitinib for TNBC that progressed after immunotherapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding a JAK1 inhibitor (ivarmacitinib) can help treat triple-negative breast cancer that stopped responding to immunotherapy. It's for people with advanced or metastatic TNBC who have already tried and failed anti-PD-1/PD-L1 treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have triple-negative breast cancer that has spread or is locally advanced.
- Your cancer got worse while or after receiving immunotherapy (like Keytruda or Tecentriq).
- You have at least one tumor that can be measured on scans.
- Your major organs (like bone marrow, liver, kidneys) are working well enough based on blood tests.
- You have not had certain other cancer treatments recently, like surgery or radiation within 3 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
This trial tests whether adding an IL-1 inhibitor (isunakinra) to standard immunotherapy (pembrolizumab) and chemotherapy can help shrink tumors in newly diagnosed, advanced triple-negative breast cancer.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a targeted therapy (olaparib) and chemotherapy (paclitaxel) before surgery for people with an aggressive type of early breast cancer called triple-negative breast cancer. It is for those whose tumors have a specific genetic feature called HRD-positive, which may make the cancer more sensitive to these treatments.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.